Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
4D-710 in Adults With Cystic Fibrosis
NCT05248230Phase 2Recruiting
- Sponsor
- 4D Molecular Therapeutics
- Start
- Mar 2022
- Primary completion
- Jun 2027
- Modality
- Gene Editing, Gene Silencing, AAV Vectors
- Countries
- 1
01
Overview
A Phase 2 trial of 4D-710 in cystic fibrosis (CF), sponsored by 4D Molecular Therapeutics. Started Mar 2022; status: recruiting.
02
Drugs
4D-710
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NCT05248230.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05248230.